{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:23:22Z","timestamp":1789212202279,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T00:00:00Z","timestamp":1360972800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s11064-013-0992-5","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T07:56:13Z","timestamp":1360914973000},"page":"866-875","source":"Crossref","is-referenced-by-count":20,"title":["Ethylenedioxy-PIP2 Oxalate Reduces Ganglioside Storage in Juvenile Sandhoff Disease Mice"],"prefix":"10.1007","volume":"38","author":[{"given":"Julian R.","family":"Arthur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Rockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Shayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,16]]},"reference":[{"key":"992_CR1","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.bbamem.2006.05.027","volume":"1758","author":"T Kolter","year":"2006","unstructured":"Kolter T, Sandhoff K (2006) Sphingolipid metabolism diseases. Biochim Biophys Acta 1758:2057\u20132079","journal-title":"Biochim Biophys Acta"},{"key":"992_CR2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","volume":"11","author":"K Sango","year":"1995","unstructured":"Sango K, Yamanaka S, Hoffmann A et al (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 11:170\u2013176","journal-title":"Nat Genet"},{"key":"992_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/5.1.1","volume":"5","author":"D Phaneuf","year":"1996","unstructured":"Phaneuf D, Wakamatsu N, Huang JQ et al (1996) Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 5:1\u201314","journal-title":"Hum Mol Genet"},{"key":"992_CR4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2990.2002.00422.x","volume":"28","author":"M Jeyakumar","year":"2002","unstructured":"Jeyakumar M, Butters TD, Dwek RA et al (2002) Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol 28:343\u2013357","journal-title":"Neuropathol Appl Neurobiol"},{"key":"992_CR5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/brain\/awg089","volume":"126","author":"M Jeyakumar","year":"2003","unstructured":"Jeyakumar M, Thomas R, Elliot-Smith E et al (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126:974\u2013987","journal-title":"Brain"},{"key":"992_CR6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2008.06.024","volume":"203","author":"S Kyrkanides","year":"2008","unstructured":"Kyrkanides S, Miller AW, Miller JN et al (2008) Peripheral blood mononuclear cell infiltration and neuroinflammation in the HexB\u2212\/\u2212 mouse model of neurodegeneration. J Neuroimmunol 203:50\u201357","journal-title":"J Neuroimmunol"},{"key":"992_CR7","doi-asserted-by":"crossref","first-page":"27108","DOI":"10.1016\/S0021-9258(18)47132-3","volume":"269","author":"FM Platt","year":"1994","unstructured":"Platt FM, Neises GR, Karlsson GB et al (1994) N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem 269:27108\u201327114","journal-title":"J Biol Chem"},{"key":"992_CR8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0962-8924(98)01249-5","volume":"8","author":"S Ichikawa","year":"1998","unstructured":"Ichikawa S, Hirabayashi Y (1998) Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol 8:198\u2013202","journal-title":"Trends Cell Biol"},{"key":"992_CR9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.neuint.2007.12.001","volume":"52","author":"RC Baek","year":"2008","unstructured":"Baek RC, Kasperzyk JL, Platt FM et al (2008) N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int 52:1125\u20131133","journal-title":"Neurochem Int"},{"key":"992_CR10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11064-012-0718-0","volume":"37","author":"JR Arthur","year":"2012","unstructured":"Arthur JR, Lee JP, Snyder EY et al (2012) Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice. Neurochem Res 37:1335\u20131343","journal-title":"Neurochem Res"},{"key":"992_CR11","doi-asserted-by":"crossref","unstructured":"Platt FM, Neises GR, Reinkensmeier G et al (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science (New York, N.Y) 276:428\u2013431","DOI":"10.1126\/science.276.5311.428"},{"key":"992_CR12","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","volume":"96","author":"M Jeyakumar","year":"1999","unstructured":"Jeyakumar M, Butters TD, Cortina-Borja M et al (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 96:6388\u20136393","journal-title":"Proc Natl Acad Sci USA"},{"key":"992_CR13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1194\/jlr.M400411-JLR200","volume":"46","author":"JL Kasperzyk","year":"2005","unstructured":"Kasperzyk JL, d\u2019Azzo A, Platt FM et al (2005) Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res 46:744\u2013751","journal-title":"J Lipid Res"},{"key":"992_CR14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1471-4159.2004.02381.x","volume":"89","author":"JL Kasperzyk","year":"2004","unstructured":"Kasperzyk JL, El-Abbadi MM, Hauser EC et al (2004) N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem 89:645\u2013653","journal-title":"J Neurochem"},{"key":"992_CR15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0006-2952(99)00384-6","volume":"59","author":"U Andersson","year":"2000","unstructured":"Andersson U, Butters TD, Dwek RA et al (2000) N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59:821\u2013829","journal-title":"Biochem Pharmacol"},{"key":"992_CR16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.nbd.2004.04.012","volume":"16","author":"U Andersson","year":"2004","unstructured":"Andersson U, Smith D, Jeyakumar M et al (2004) Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis 16:506\u2013515","journal-title":"Neurobiol Dis"},{"key":"992_CR17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ymgme.2008.02.005","volume":"94","author":"E Elliot-Smith","year":"2008","unstructured":"Elliot-Smith E, Speak AO, Lloyd-Evans E et al (2008) Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol Genet Metab 94:204\u2013211","journal-title":"Mol Genet Metab"},{"key":"992_CR18","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","volume":"5","author":"J Marshall","year":"2010","unstructured":"Marshall J, Ashe KM, Bangari D et al (2010) Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS ONE 5:e15033","journal-title":"PLoS ONE"},{"key":"992_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","volume":"33","author":"J Marshall","year":"2010","unstructured":"Marshall J, McEachern KA, Chuang WL et al (2010) Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 33:281\u2013289","journal-title":"J Inherit Metab Dis"},{"key":"992_CR20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","volume":"18","author":"CE Hollak","year":"2009","unstructured":"Hollak CE, Hughes D, van Schaik IN et al (2009) Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 18:770\u2013777","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"992_CR21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA et al (2010) A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116:893\u2013899","journal-title":"Blood"},{"key":"992_CR22","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA et al (2010) Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116:4095\u20134098","journal-title":"Blood"},{"key":"992_CR23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/03009734.2011.641609","volume":"117","author":"M Machaczka","year":"2012","unstructured":"Machaczka M, Hast R, Dahlman I et al (2012) Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution. Ups J Med Sci 117:28\u201334","journal-title":"Ups J Med Sci"},{"key":"992_CR24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","volume":"35","author":"JA Shayman","year":"2010","unstructured":"Shayman JA (2010) ELIGLUSTAT TARTRATE: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 35:613\u2013620","journal-title":"Drugs Future"},{"key":"992_CR25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","volume":"26","author":"TM Cox","year":"2003","unstructured":"Cox TM, Aerts JM, Andria G et al (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26:513\u2013526","journal-title":"J Inherit Metab Dis"},{"key":"992_CR26","first-page":"1169","volume":"11","author":"TM Cox","year":"2010","unstructured":"Cox TM (2010) Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 11:1169\u20131181","journal-title":"Curr Opin Investig Drugs"},{"key":"992_CR27","doi-asserted-by":"crossref","first-page":"29052","DOI":"10.1074\/jbc.M705005200","volume":"282","author":"B Brumshtein","year":"2007","unstructured":"Brumshtein B, Greenblatt HM, Butters TD et al (2007) Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem 282:29052\u201329058","journal-title":"J Biol Chem"},{"key":"992_CR28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","volume":"35","author":"P Alfonso","year":"2005","unstructured":"Alfonso P, Pampin S, Estrada J et al (2005) Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis 35:268\u2013276","journal-title":"Blood Cells Mol Dis"},{"key":"992_CR29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","volume":"91","author":"KA McEachern","year":"2007","unstructured":"McEachern KA, Fung J, Komarnitsky S et al (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91:259\u2013267","journal-title":"Mol Genet Metab"},{"key":"992_CR30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1194\/jlr.M021261","volume":"53","author":"SD Larsen","year":"2012","unstructured":"Larsen SD, Wilson MW, Abe A et al (2012) Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res 53:282\u2013291","journal-title":"J Lipid Res"},{"key":"992_CR31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/000456327901600192","volume":"16","author":"H Galjaard","year":"1979","unstructured":"Galjaard H (1979) Early diagnosis and prevention of genetic disease. Ann Clin Biochem 16:343\u2013353","journal-title":"Ann Clin Biochem"},{"key":"992_CR32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11745-008-3268-0","volume":"44","author":"RC Baek","year":"2009","unstructured":"Baek RC, Martin DR, Cox NR et al (2009) Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids 44:197\u2013205","journal-title":"Lipids"},{"key":"992_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/B:BIGI.0000034429.55418.71","volume":"42","author":"EC Hauser","year":"2004","unstructured":"Hauser EC, Kasperzyk JL, d\u2019Azzo A et al (2004) Inheritance of lysosomal acid beta-galactosidase activity and gangliosides in crosses of DBA\/2J and knockout mice. Biochem Genet 42:241\u2013257","journal-title":"Biochem Genet"},{"key":"992_CR34","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0022-2275(20)37906-2","volume":"24","author":"LJ Macala","year":"1983","unstructured":"Macala LJ, Yu RK, Ando S (1983) Analysis of brain lipids by high performance thin-layer chromatography and densitometry. J Lipid Res 24:1243\u20131250","journal-title":"J Lipid Res"},{"key":"992_CR35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00484473","volume":"17","author":"TN Seyfried","year":"1979","unstructured":"Seyfried TN, Glaser GH, Yu RK (1979) Genetic variability for regional brain gangliosides in five strains of young mice. Biochem Genet 17:43\u201355","journal-title":"Biochem Genet"},{"key":"992_CR36","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/BF00484350","volume":"18","author":"TN Seyfried","year":"1980","unstructured":"Seyfried TN, Yu RK (1980) Heterosis for brain myelin content in mice. Biochem Genet 18:1229\u20131238","journal-title":"Biochem Genet"},{"key":"992_CR37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nm1548","volume":"13","author":"JP Lee","year":"2007","unstructured":"Lee JP, Jeyakumar M, Gonzalez R et al (2007) Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 13:439\u2013447","journal-title":"Nat Med"},{"key":"992_CR38","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1471-4159.2010.06733.x","volume":"113","author":"CA Denny","year":"2010","unstructured":"Denny CA, Heinecke KA, Kim YP et al (2010) Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice. J Neurochem 113:1525\u20131535","journal-title":"J Neurochem"},{"key":"992_CR39","doi-asserted-by":"crossref","first-page":"e21758","DOI":"10.1371\/journal.pone.0021758","volume":"6","author":"KM Ashe","year":"2011","unstructured":"Ashe KM, Bangari D, Li L et al (2011) Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLoS ONE 6:e21758","journal-title":"PLoS ONE"},{"key":"992_CR40","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1046\/j.1471-4159.1998.70020871.x","volume":"70","author":"JV Brigande","year":"1998","unstructured":"Brigande JV, Platt FM, Seyfried TN (1998) Inhibition of glycosphingolipid biosynthesis does not impair growth or morphogenesis of the postimplantation mouse embryo. J Neurochem 70:871\u2013882","journal-title":"J Neurochem"},{"key":"992_CR41","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","volume":"269","author":"FM Platt","year":"1994","unstructured":"Platt FM, Neises GR, Dwek RA et al (1994) N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269:8362\u20138365","journal-title":"J Biol Chem"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-013-0992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-013-0992-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-013-0992-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T02:57:32Z","timestamp":1714964252000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-013-0992-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,16]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1007\/s11064-013-0992-5","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,16]]}}}